all the latest information
therapeutic class and intervention. Listed below are recently updated therapeutic classes.
Influence of rate of neutrophil recovery on the incidence of GvHD
In a retrospective study, recently published in Transplant International, Takashi Nagayama and colleagues evaluated the influence of...
FDA rejects remestemcel-L for the treatment of steroid-refractory aGvHD pending further study
The FDA have issued a complete response letter rejecting the application of a Biologics License...
The impact of JAK inhibitor use on HSCT outcome in patients with MPN
Barabanshikova and colleagues analyzed outcomes of patients with MPN undergoing allo-HSCT with or without prior JAK inhibitor...
Use of ruxolitinib in patients with severe COVID-19
A summary of the prospective observational study by the RUXO-COVID Study Group assessing response to ruxolitinib treatment in 34 patients with...
KD025 for chronic GvHD: an update
During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) two posters were presented by Madan Jagasia on KD025 (belumosudil).
New Drug Application submitted for belumosudil to FDA
A submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) was made for the Rho-associated coiled coil kinase 2...
Phase II results of natalizumab plus steroids for gastrointestinal GvHD
Natasha Kekre and colleagues conducted a phase II clinical trial to investigate the safety and efficacy of an antibody targeting...
Antithymocyte globulin decreases acute graft-versus-host disease following HLA-matched sibling donor transplantation
Results from a multicenter, open-label, randomized controlled trial were recently...
Mesenchymal stromal cells
Chemokine receptor antagonists
Fecal microbiota transplant
Nuclear receptor agonists